HideChilds = False
SystemName = Homepage

Bioverativ – Science matters. Because patients matter.

Science matters.
Because patients matter.

Learn more

Science that redefines what's possible

Our scientists brought the first major advances in hemophilia treatment in nearly two decades, and we’re committed to developing new, life-changing medicines for people with rare blood disorders.

Learn more

Expanding access around the world

We committed, with Sobi, to donate up to 1 billion IUs of factor therapy to the developing world. Already, more than 15,000 people with hemophilia have been treated.

Learn more

Bioverativ in the news

Wednesday, February 14, 2018 7:00 AM

Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A

Read more